A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

Registration

Registration

NCT07141914

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

285327

Start

2025-08-29

Primary completion

2025-12-19

Lead sponsor

Novo Nordisk A/S

Conditions

Overweight; Obesity; Heart Failure (HF); Atherosclerotic Cardiovascular Disease (ASCVD); Primary Prevention

Interventions

OTHER:No treatment given

Results posted

FALSE

Individual participant data sharing

YES

Secondary identifiers

OTHER:U1111-1326-1795

Registered primary outcomes

• Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) [Index date, earliest of revised MACE-5 and end of follow-up; up to 42 months]
• Revised 3-point Major Adverse Cardiovascular Events MACE-3 (time-to-event) [Index date, earliest of revised MACE-3 and end of follow-up; up to 42 months]